Agenus director receives stock option grants at $3.90

Agenus Inc. director and officer Armen Garo H received three stock option awards on April 24, 2026.

Rhea-AI Filing Summary

Agenus Inc. director and officer Armen Garo H received three stock option awards on April 24, 2026. Each option allows him to purchase Agenus common stock at an exercise price of $3.90 per share and expires on April 24, 2036. One award is scheduled to vest over three years beginning April 24, 2027, and another was granted in lieu of his 2025 annual cash bonus and will vest in full on May 24, 2026.

Insider Trade Summary

Grant/Award: 1,165,300 shares

Grant/Award 3 txns

Insider ARMEN GARO H

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	1,000,000	$0.00	$0.00
Grant/Award	Stock Option	27,750	$0.00	$0.00
Grant/Award	Stock Option	137,550	$0.00	$0.00

Holdings After Transaction: Stock Option — 1,165,300 contracts (Direct)

Footnotes (2)

1. F1. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on April 24, 2027, and the balance vesting in equal quarterly installments thereafter.
2. F2. Option awarded in lieu of the 2025 annual cash bonus and in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. Vests in full on May 24, 2026.

Key Figures

Stock option grant 1 size: 137,550 options Stock option grant 2 size: 27,750 options Stock option grant 3 size: 1,000,000 options +4 more

7 metrics

Stock option grant 1 size 137,550 options Underlying Agenus common stock; grant on April 24, 2026

Stock option grant 2 size 27,750 options Underlying Agenus common stock; grant on April 24, 2026

Stock option grant 3 size 1,000,000 options Underlying Agenus common stock; grant on April 24, 2026

Exercise price $3.90 per share Conversion or exercise price for each stock option award

Option expiration April 24, 2036 Expiration date for each stock option grant

Vesting start milestone April 24, 2027 One-third of a grant vests on this date; remaining vests quarterly

Bonus replacement vesting date May 24, 2026 Grant awarded in lieu of 2025 annual cash bonus vests in full

Key Terms

Stock Option, Grant, award, or other acquisition, Equity Incentive Plan, annual cash bonus

4 terms

Stock Option financial

"security_title": "Stock Option""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Equity Incentive Plan financial

"Agenus Inc. 2019 Amended and Restated Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

annual cash bonus financial

"Option awarded in lieu of the 2025 annual cash bonus"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Agenus (AGEN) report for Armen Garo H?

Agenus reported that director and officer Armen Garo H received three stock option awards on April 24, 2026. These options are compensation grants, not open-market purchases or sales, and give rights to acquire Agenus common stock at a fixed exercise price over time.

What are the key terms of the new Agenus (AGEN) stock options?

The new awards are stock options to acquire Agenus common stock at an exercise price of $3.90 per share, expiring on April 24, 2036. They are classified as derivative securities and were granted directly to Armen Garo H as part of his compensation.

How do the Agenus (AGEN) options granted to Armen Garo H vest?

One option award vests over three years, with one-third vesting on April 24, 2027 and the remainder in equal quarterly installments. Another option, granted in lieu of the 2025 annual cash bonus, is scheduled to vest in full on May 24, 2026.

Were the Agenus (AGEN) stock options an open-market transaction?

No. The filing identifies each transaction with code “A”, meaning a grant, award, or other acquisition. These are compensation-related stock option grants under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, not open-market buys or sells of existing shares.

What plan governs the new Agenus (AGEN) stock option grants?

The options were awarded under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. One award is a standard equity incentive grant with time-based vesting, while another replaces a 2025 annual cash bonus with equity, aligning compensation more closely with stock performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/28/2026 - 04:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ARMEN GARO H

(Last) (First) (Middle)

C/O AGENUS INC.

3 FORBES ROAD

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AGENUS INC [ AGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$3.9	04/24/2026		A		1,000,000		(1)	04/24/2036	Common Stock	1,000,000	$0.00	1,000,000	D
Stock Option	$3.9	04/24/2026		A		27,750		(1)	04/24/2036	Common Stock	27,750	$0.00	27,750	D
Stock Option	$3.9	04/24/2026		A		137,550		(2)	04/24/2036	Common Stock	137,550	$0.00	137,550	D

Explanation of Responses:

1. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests over three years with one-third of the award vesting on April 24, 2027, and the balance vesting in equal quarterly installments thereafter.

2. Option awarded in lieu of the 2025 annual cash bonus and in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. Vests in full on May 24, 2026.

Remarks:

Chairman, Chief Executive Officer and Principal Financial Officer

	/s/ Austin Charette, as Attorney-in-Fact for Garo H. Armen	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)